MA30427B1 - Derives bicycliques utilises comme inhibiteurs de cetp - Google Patents

Derives bicycliques utilises comme inhibiteurs de cetp

Info

Publication number
MA30427B1
MA30427B1 MA31408A MA31408A MA30427B1 MA 30427 B1 MA30427 B1 MA 30427B1 MA 31408 A MA31408 A MA 31408A MA 31408 A MA31408 A MA 31408A MA 30427 B1 MA30427 B1 MA 30427B1
Authority
MA
Morocco
Prior art keywords
derivatives used
cetp inhibitors
bicyclic derivatives
cetp
bicyclic
Prior art date
Application number
MA31408A
Other languages
English (en)
Inventor
Masashi Kishida
Naoko Matsuura
Hidetomo Imase
Yuki Iwaki
Ichiro Umemura
Osamu Ohmori
Eiji Kawahara
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0609268.8A external-priority patent/GB0609268D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30427B1 publication Critical patent/MA30427B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DE NOUVEAUX COMPOSÉS DE FORMULE (I), OU UNE COMPOSITION PHARMACEUTIQUE DESDITS COMPOSÉS, TOUTES LES VARIABLES ÉTANT DÉFINIES DANS LE TEXTE. ELLE CONCERNE ÉGALEMENT L'UTILISATION DE CES COMPOSÉS AUX FINS DE TRAITER OU DE RETARDER L'ÉVOLUTION DE MALADIES APPARENTES DANS LESQUELLES CETP EST IMPLIQUÉE.
MA31408A 2006-05-10 2008-11-24 Derives bicycliques utilises comme inhibiteurs de cetp MA30427B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0609268.8A GB0609268D0 (en) 2006-05-10 2006-05-10 Organic compounds
US86648006P 2006-11-20 2006-11-20
US89614207P 2007-03-21 2007-03-21

Publications (1)

Publication Number Publication Date
MA30427B1 true MA30427B1 (fr) 2009-05-04

Family

ID=38445602

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31408A MA30427B1 (fr) 2006-05-10 2008-11-24 Derives bicycliques utilises comme inhibiteurs de cetp

Country Status (17)

Country Link
US (2) US8232403B2 (fr)
EP (1) EP2024356A1 (fr)
KR (1) KR101172120B1 (fr)
AR (1) AR060873A1 (fr)
AU (1) AU2007247385B2 (fr)
CA (1) CA2650954C (fr)
CL (1) CL2007001325A1 (fr)
CR (1) CR10420A (fr)
EC (1) ECSP088891A (fr)
GT (1) GT200800242A (fr)
IL (1) IL195010A0 (fr)
MA (1) MA30427B1 (fr)
MX (1) MX2008014284A (fr)
NO (1) NO20084912L (fr)
TN (1) TNSN08444A1 (fr)
TW (1) TW200813009A (fr)
WO (1) WO2007128568A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1848430T3 (da) 2004-12-31 2017-11-06 Dr Reddys Laboratories Ltd Nye benzylamin-derivativer som cetp-inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
KR20080086917A (ko) * 2005-12-29 2008-09-26 노파르티스 아게 콜레스테릴 에스테르 전달 단백질 (ｃｅｔｐ) 억제제로서의피리디닐 아민 유도체
WO2007128568A1 (fr) * 2006-05-10 2007-11-15 Novartis Ag Dérivés bicycliques utilisés comme inhibiteurs de cetp
BRPI0711447A2 (pt) * 2006-05-11 2011-11-08 Novartis Ag compostos orgánicos
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
MX2009010962A (es) 2007-04-13 2009-12-16 Kowa Co Compuesto pirimidina novedoso que tiene estructura de dibencilamina y medicamento que comprende el mismo.
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
JP5478508B2 (ja) 2008-11-28 2014-04-23 興和株式会社 ｔｒａｎｓ−｛４−［（アルキルアミノ）メチル］シクロヘキシル｝酢酸エステルの製造方法
EA021275B9 (ru) * 2009-09-03 2015-08-31 Байоэнердженикс Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (fr) 2011-03-08 2014-12-17 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
WO2012120056A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
PL2729142T3 (pl) 2011-07-08 2018-10-31 Novartis Ag Sposób leczenia miażdżycy tętnic u osobników z wysokim poziomem triglicerydów
CA2845284C (fr) 2011-08-18 2018-03-06 Dr. Reddy's Laboratories Ltd. Composes amines heterocycliques substitues comme inhibiteurs de la proteine de transfert d'ester cholesterylique (cetp)
JP6140168B2 (ja) 2011-09-27 2017-05-31 ドクター レディズ ラボラトリーズ リミテッド アテローム性動脈硬化症の処置のために有用なコレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての５−ベンジルアミノメチル−６−アミノピラゾロ［３，４−ｂ］ピリジン誘導体
CA2891502A1 (fr) * 2012-11-19 2014-05-22 Dr. Reddy's Laboratories Ltd. Compositions pharmaceutiques d'inhibiteurs de cetp
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US20160000799A1 (en) * 2013-02-21 2016-01-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
US9266925B2 (en) 2013-07-25 2016-02-23 Novartis Ag Cyclic polypeptides for the treatment of heart failure
BR112016001376A2 (pt) 2013-07-25 2017-10-24 Novartis Ag bioconjugados de polipeptídeos de apelin sintéticos
CA2972871A1 (fr) 2015-01-23 2016-07-28 Novartis Ag Conjugues d'acides gras de l'apeline synthetique presentant une demi-vie amelioree
US12162863B2 (en) 2018-06-12 2024-12-10 Ryvu Therapeutics S.A. Modulators of stimulator of interferon genes (STING)
IL288868B2 (en) 2019-06-12 2025-02-01 Ryvu Therapeutics S A Next generation of stimulator of interferon genes (STING) modulators
KR20260022465A (ko) * 2019-12-11 2026-02-19 리부 세라퓨틱스 에스.에이. 인터페론 유전자 자극제(sting)의 조절제인 헤테로사이클릭 화합물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451823B1 (en) * 1999-09-23 2002-09-17 G.D. Searle & Co. Use of substituted N-phenoxy-N-phenyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
CA2420967A1 (fr) * 2000-08-07 2002-02-14 Neurogen Corporation Composes heterocycliques en tant que ligands du recepteur gabaa
ES2277142T3 (es) 2002-08-30 2007-07-01 Japan Tobacco Inc. Compuesto de dibencilamina y su uso medicinal.
ATE552253T1 (de) 2002-11-08 2012-04-15 Novartis Int Pharm Ltd 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren
CN1795177A (zh) 2003-03-28 2006-06-28 辉瑞产品公司 作为治疗动脉粥样硬化和肥胖症的cetp抑制剂的 1 , 2 , 4 , －取代的1，2，3，4，－四氢－和1，2二氢－喹啉以及1， 2 , 3 ， 4－四氢－喹喔啉衍生物
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7737295B2 (en) 2004-04-13 2010-06-15 Merck Sharp & Dohme Corp. CETP inhibitors
CA2589322A1 (fr) 2004-11-23 2006-06-01 Pfizer Products Inc. Composes et derives de dibenzyl amine
US7668830B2 (en) 2004-11-29 2010-02-23 Nokia Corporation Access rights
DK1848430T3 (da) * 2004-12-31 2017-11-06 Dr Reddys Laboratories Ltd Nye benzylamin-derivativer som cetp-inhibitors
WO2007075194A1 (fr) 2005-12-28 2007-07-05 Reddy Us Therapeutics, Inc. Derives de benzylamine selectifs et leur utilite en tant qu’inhibiteurs de la proteine de transfert de l'ester de cholesterol
EP1834490A1 (fr) 2005-01-06 2007-09-19 Thomson Licensing Reduction d'artefacts d'arc-en-ciel dans des systemes numeriques de projection de lumiere
US20100203504A1 (en) 2005-07-07 2010-08-12 Yoichi Katsumoto Substance-Information Acquisition Method Using Evanescent Light Beam, Substance-Information Measurement Apparatus, Base-Sequence Determination Method and Base-Sequence Determination Apparatus
US7573978B2 (en) 2005-07-11 2009-08-11 University Of Florida Research Foundation, Inc. Variable feathering field splitting for intensity modulated fields of large size
KR20080086917A (ko) * 2005-12-29 2008-09-26 노파르티스 아게 콜레스테릴 에스테르 전달 단백질 (ｃｅｔｐ) 억제제로서의피리디닐 아민 유도체
UY30118A1 (es) * 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compueto amina trisustituido
WO2007128568A1 (fr) * 2006-05-10 2007-11-15 Novartis Ag Dérivés bicycliques utilisés comme inhibiteurs de cetp
BRPI0711447A2 (pt) * 2006-05-11 2011-11-08 Novartis Ag compostos orgánicos
MX2009005249A (es) * 2006-11-15 2009-05-28 Novartis Ag Compuestos organicos.
CN101535293A (zh) * 2006-11-15 2009-09-16 诺瓦提斯公司 作为cetp抑制剂的杂环衍生物

Also Published As

Publication number Publication date
AU2007247385A1 (en) 2007-11-15
WO2007128568A1 (fr) 2007-11-15
AR060873A1 (es) 2008-07-16
CA2650954A1 (fr) 2007-11-15
US20120225874A1 (en) 2012-09-06
MX2008014284A (es) 2008-11-18
NO20084912L (no) 2009-02-03
IL195010A0 (en) 2009-08-03
US8410275B2 (en) 2013-04-02
KR20090017580A (ko) 2009-02-18
KR101172120B1 (ko) 2012-08-10
CL2007001325A1 (es) 2008-07-18
AU2007247385B2 (en) 2011-07-14
TW200813009A (en) 2008-03-16
US8232403B2 (en) 2012-07-31
TNSN08444A1 (en) 2010-04-14
EP2024356A1 (fr) 2009-02-18
GT200800242A (es) 2009-04-29
ECSP088891A (es) 2008-12-30
CA2650954C (fr) 2014-02-11
CR10420A (es) 2009-02-02
US20090227580A1 (en) 2009-09-10

Similar Documents

Publication Publication Date Title
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA31586B1 (fr) Dérivés d'alcools alkyliques de 1-phényl-2-pyridinyle en tant qu'inhibiteurs de la phosphodiestérase
EP1784188A4 (fr) Derives de triazole accoles inhibiteurs de la dipeptidyl peptidase-iv utilises dans le traitement ou la prevention du diabete
EP1592689A4 (fr) Derives d'acide 3-amino-4-phenylbutanoique utilises comme inhibiteurs de dipeptidyle peptidase pour le traitement ou la prevention du diabete
EP1589969A4 (fr) Derives d'acide 3-amino-4-phenylbutanoique utilises comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
MA32104B1 (fr) Dérivés d'oxime en tant qu'inhibiteurs de hsp90
EP1796669A4 (fr) Aminopiperidines utilisees comme inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MA27559A1 (fr) Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation
MA31000B1 (fr) Derives 2-aza-bicyclo[3.1.0]hexane
DE602004011330D1 (de) Imidazo- und thiazolopyridine als jak3-kinase-inhibitoren
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
EP1888066A4 (fr) Aminocyclohexanes en tant qu'inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete
MA29535B1 (fr) Derives d'isoquinoline utilises en tant qu'inhibiteurs de rhokinase
EA200601007A1 (ru) 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
EA200970519A1 (ru) Полиморфы сукцината 2-[6-(3-аминопиперидин-1-ил)-3-метил-2,4-диоксо-3,4-дигидро-2h-пиримидин-1-илметил]-4-фторбензонитрил и способы их применения
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
EP1921917A4 (fr) Aminopiperidines fusionnees utilisees comme inhibiteurs de dipeptidyl-peptidase-iv pour le traitement ou la prevention du diabete
MA27556A1 (fr) Derives de phenylalanine comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
TNSN08038A1 (en) Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
MA31021B1 (fr) Derives de l'isoquinoleine et de l'isoquinoleinone substituees en tant qu'inhibiteurs de la rho-kinase
MY148479A (en) Piperidinyl-substituted isoquinolone derivatives
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer